Protara Therapeutics, Inc. — Director's Dealing 2017

May 5, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-04-27

Reporting Person: Kowalsky Matthew Paul (VP, Legal and Secretary)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value	3097	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.16	2026-05-22	Common Stock, $0.001 par value (50000)		Direct
Stock Option (Right to Buy)	$2.05	2027-01-23	Common Stock, $0.001 par value (58431)		Direct

Footnotes

F1: The options were granted on May 23, 2016 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

F2: The options were granted on January 24, 2017 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.